Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Despite being hit by a succession of vaccine scandals and resulting public fears of domestically produced biologics, China's leading vaccine developer could ultimately emerge as a more powerful player due to its sterling reputation in a field of tarnished competitors
You may also be interested in...
China Drug Safety Remains Front and Center In Chromium Capsule Scandal
China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.
China Drug Safety Remains Front And Center In Chromium Capsule Scandal
China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.
Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine
BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines